Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Definium TherapeuticsDFTX -3.47%32 EV-to-EBITDA is -23.86 as of Jul. 17, 2026. GuruFocus rates DFTX with a GF Score™ of 32/100. The stock has 5 warning signs investors should review. Among 395 Biotechnology companies, Definium Therapeutics ranks worse than 253164.3% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Definium Therapeutics's enterprise value is $5,521.33 Mil.
Definium Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-231.42 Mil. Therefore, Definium Therapeutics's EV-to-EBITDA for today is -23.86.
The historical rank and industry rank for Definium Therapeutics's EV-to-EBITDA or its related term are showing as below:
DFTX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -25.95 Med: 0 Max: 0
Current: -23.86
DFTX's EV-to-EBITDA is ranked worse than 100% of 395
companies
in the Biotechnology industry
Industry Median: 13
vs DFTX: -23.86
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Definium Therapeutics's PE Ratio (TTM) for today is calculated as:
Definium Therapeutics's share price for today is $44.11.
Definium Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.490.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Definium Therapeutics EV-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Definium Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Definium Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Definium Therapeutics EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Definium Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Definium Therapeutics's EV-to-EBITDA falls into.
Definium Therapeutics's current Enterprise Value is $5,521.33 Mil.
Definium Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-231.42 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Definium Therapeutics (DFTX) has a EV-to-EBITDA of -23.86 as of Jul. 17, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Definium Therapeutics. According to the industry distribution chart, Definium Therapeutics ranks #999999 out of 395 companies in the Biotechnology industry.
Is Definium Therapeutics' EV-to-EBITDA too high?
Definium Therapeutics' current EV-to-EBITDA is -23.86. Based on the distribution chart, Definium Therapeutics ranks #999999 out of 395 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Definium Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Definium Therapeutics' EV-to-EBITDA compare to LGND and XENE?
According to the Biotechnology industry distribution chart, Definium Therapeutics ranks #999999 out of 395 companies for EV-to-EBITDA. This places Definium Therapeutics in the lower half of its industry. The industry median EV-to-EBITDA is 13.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.00, based on 395 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Definium Therapeutics. For the Biotechnology industry, the median EV-to-EBITDA is 13.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Definium Therapeutics's current EV-to-EBITDA is -23.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Definium Therapeutics stock overvalued right now?
Definium Therapeutics (DFTX) has a current EV-to-EBITDA of -23.86. The current EV-to-EBITDA is -23.86. Definium Therapeutics' overall GF Score™ is 32/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Definium Therapeutics (DFTX), the current EV-to-EBITDA is -23.86 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.
32GF Score
Get the complete analysis for DFTX
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DFTX has been successfully added to your 
